A randomized, double-blind, placebo-controlled cross-over study of adjuvant treatment with remacemide hydrochloride was carried out in 17 patients taking sodium valproate (VPA) as monotherapy. Plasma concentration profiles of VPA, remacemide, and its active desglycinyl metabolite (ARL12495XX) were determined following single (300 mg) and multiple dosing (150 or 300 mg twice daily) of remacemide hydrochloride for 14 days with a 300-mg final dose. Central nervous system side-effects were more common at the higher dose, which prompted dosage reduction to 150 mg twice daily for subsequent patients partway through the study. The mean area under the concentration-time curve, peak concentration and pre-dose concentration of VPA were unchanged by remacemide hydrochloride in three patients on the higher and in 10 patients on the lower dose of remacemide. The pharmacokinetic parameters of remacemide and its active metabolite in the VPA-treated patients were similar to those described previously in healthy volunteers. Thus, remacemide hydrochloride does not interfere with the pharmacokinetics of VPA and vice versa.
INTRODUCTION
Remacemide hydrochloride (2-amino-N-[lmethyl-1,2-diphenylethyll-acetamide monohydrochloride), a novel anticonvulsant, is a noncompetitive antagonist at N-methyl-D-aSpartate (NMDA) receptors'. Metabolism in man involves production of an active desglycinyl metabolite2, ARL12495XX, which has a longer elimination half-life than the parent compound (12-18 s 3-4 hours)3, and is a potent antagonist at the NMDA receptor4. As well as being an anticonvulsant5, remacemide hydrochloride could be effective in preventing cell damage in the course of ischaemic injury6 and in Parkinson's disease'. Previous studies have demonstrated a modest inhibitory effect of remacemide on carbamazepine metabolism, and induction of remacemide metabolism by carbamazepine and phenytoinsV9.
Sodium valproate (VPA) is a first-line anticonvulsant drug, which is effective for generalized and partial seizures". Cognitive effects are less severe with VPA than with other antiepileptic drugs (AEDs), and its use has been recommended where psychomotor performance is an important consideration"*'2. Drug interactions are less troublesome with VPA than with enzyme-inducing AEDs13, although it has some minor enzyme-inhibiting properties14. The predilection of the established AEDs to interact with other compounds and the need for novel agents to be used as adjunctive therapy require early assessment of potential pharmacokinetic interactions, which can obscure interpretation of trial results and influence dose selection. This pharmacokinetic interaction study with remacemide hydrochloride was carried out in patients on VPA monotherapy, using a randomized, double-blind, placebo-controlled, cross-over design15.
METHODS

Patients
A total of 17 patients were recruited (Table l) , each taking a regimen of VPA twice daily as monotherapy which had been stable for at least 3 months. All patients had at least one plasma measurement of valproic acid within the target J.P. Leach et a/. All patients were free from hepatic, renal, or haematological disease. They were asked to refrain from alcohol and caffeine throughout the study. Some patients were on a stable dose of other medication, none of which was known to interact with VPA or remacemide hydrochloride. Patients were required to keep a diary card detailing seizure type and frequency and the duration and nature of any adverse events experienced.
Compliance was checked by questioning the patients and carrying out a tablet count.
Protocol
The study had a double-blind, random order, placebo-controlled, cross-over design, preceded by an open, single-dose treatment phase. Patients continued to take VPA twice daily in their usual dose throughout. One week following a screening visit, each patient received 300 mg remacemide hydrochloride.
Plasma levels of VPA, remacemide, and ARL12495XX, were measured 0, 0.5, 1, 1.5,2,4,6, 8, 10, 12,24, and 48 hours after dosing. One week later, patients entered the first arm of chronic treatment, receiving either remacemide hydrochloride or matched placebo. The total treatment period was 14 days (100mg twice daily on day 2,200 mg twice daily on day 3 and 300 mg twice daily thereafter), after which a final 300-mg dose of remacemide hydrochloride was given on the morning of day 15 to allow measurement of steady-state and washout concentrations at the same times after dosing as described earlier. Seven days later, the second treatment phase commenced and the whole procedure was repeated. Morning pre-dose (trough) samples were taken on days 5, 12 and 15 after initiation of treatment.
As 300 mg remacemide hydrochloride twice daily was poorly tolerated, the protocol was amended partway through the study, and patients subsequently received 150 mg twice daily with a 300-mg final dose.
All blood samples were taken into heparinized tubes from a cannulated forearm vein, which was kept patent between aspirations with normal saline. The first 1 ml withdrawn was discarded, and the subsequent 15 ml were chillled until centrifugation.
All samples were spun at 3000 rpm for 10 minutes, and the separated plasma frozen at -4°C for batch analysis.
Assays
Remacemide and ARL12495XX
were quantified by high performance liquid chromatography (HPLC). This was a modification of a previously reported methodr6, adjusted to allow automated sample preparation and improved selectivity. The method involved solid phase extraction of the analytes and internal standard followed by separation on a reverse phase HPLC system utilizing an octadecyl (C-18) HPLC column, an acetonitrile based eluent, and ultraviolet detection at 210nm. Limits of quantification for the two analytes were 10 rig/ml. Only samples from the active leg of the double-blind phase were analysed for remacemide and ARL12495XX. VPA was measured by gas chromatography. Plasma samples were acidified prior to extraction into chloroform and the organic phase was analysed directly by gas chromatography on a DB-was analytical column (20m, film thickness 0.3 pm, 0.18 pm internal diameter) using flame ionization. The limit of quantification for this method was 50 pmolll of VPA.
Pharmacokinetics
The following non-compartmental pharmacokinetic parameters were computed for VPA for all three phases of serial blood sampling: (1) area under the concentration-time curve over the 12-hour dosing interval (A&=) calculated using the linear trapezoidal method; (2) peak concentration (C,,,) over the dosing interval; (3) pre-dose concentration (C,in) over the dosing interval; (4) time to maximum concentrations (7',',,X) over the dosing interval; (5) trough concentrations 5,'12, and 15 days after initiation of multiple dosing with remacemide hydrochloride or placebo.
For remacemide and ARL12495XX, the parameters calculated following single and multiple dosing were: (1) C,,,; (2) Cmin (multiple dose only); (3) T',,,; (4) A, either extrapolated to infinite time (AT) which was calculated from A = A, + C,/k, where A, = area under the curve up to the last point at which the concentration could be quantified, C, = last quantifiable concentration, and k = the terminal phase plasma elimination rate constant, or over a 1Zhour dosing interval (A&; (5) Terminal elimination half-life, (tin) after the single dose and during washout of the multiple dose remacemide hydrochloride treatment phase (this was calculated from tin = 0.693/k); (6) trough concentrations 5, 12 and 15 days into remacemide hydrochloride treatment-linear superposition of the single dose profiles was performed to determine the predictability of the multiple-dose profiles obtained.
Statistics
Statistical comparisons of the pharmacokinetic parameters obtained for VPA at the end of the multiple-dose phase of the study were compared using analysis of variance (ANOVA) with treatment, period, sequence and-patient as factors. Logarithmically transformed data were used for analysis of the AsT, C,,, and Cmin comparisons. Untransformed data were used for T,,. Analysis of the trough concentrations used ANOVA for the three concentrations per patient (5,12, and 15 days after initiation of multiple dosing) with factors for treatment, period, sequence, day number and patient. Single-and multiple-dose phases were compared using a non-parametric procedure: the matched pairs Wilcoxon signed rank test. a probability of ~5% indicated statistical significance.
RESULTS
Patients
Of the 17 patients detailed (Table l) , four completed the study at the higher dose of remacemide hydrochloride. A further 11 completed the trial having received 150 mg twice daily for at least 9 days. Patients 003,009 and 018 were not included in pharmacokinetic analyses (Table  1) . Two patients taking remacemide hydrochloride withdrew due to adverse events (one at each dose level).
VPA pharmacokinetics
Analysis of VPA pharmacokinetic data from 10 patients administered single or multiple doses (low-dose group) of remacemide hydrochloride showed no statistically significant changes over placebo ( Fig. 1; from those expected from the single-dose AUC data (Table 4) . Similarly, for the low-dose regimen, the multiple-dose exposure was not at variance with that expected based on the singledose data and taking account of the dosing regimen employed (Table 3) . These results suggest that linear kinetics prevail, and prove that there is no autoinduction of remacemide or ARL12495XX metabolism. The serial trough  concentrations  for  remacemide  and  ARL12495XX did not demonstrate any trend with time in either direction. This is evidence to support the hypothesis that steady-state had been reached by days and that no autoinduction or accumulation occurred thereafter.
Adverse events
Of the nine patients started on remacemide hydrochloride 300 mg twice daily, three were withdrawn from the study. One patient withdrew after 14 days of multiple dosing with remacemide hydrochloride (300 mg bd) due to central nervous system (CNS) side-effects. One patient withdrew after 12 days of multiple dosing with remacemide hydrochloride (5 days at 300mg bd, 7 days at 150 mg bd) due to gastro-intestinal effects. A third patient was withdrawn due to intercurrent illness after completing multiple dosing with remacemide hydrochloride (300 mg bd) but was re-entered into the beginning of the double-blind phase after an increase in VPA dosage (1500-1700mg/day).
Two other patients had their remacemide hydrochloride dose reduced to 150 mg twice daily after 4 days, and completed the trial satisfactorily at this dose level. The side-effects experienced at the higher dose were CNS related (dizziness, drowsiness, fatigue) with one patient developing dyspepsia, which failed to resolve on reducing the remacemide hydrochloride dose.
A similar number of patients reported adverse events during dosing with remacemide hydrochloride 150 mg twice daily (seven patients) and placebo (five patients). More adverse events were reported, however, while patients were receiving remacemide hydrochloride treatment (n = 21) compared with placebo (n = 8), particularly CNS side-effects (active treatment-10 events;
placebo-l event). Gastrointestinal symptoms were reported by two patients during active treatment, with none occurring on placebo.
DISCUSSION
Remacemide is eliminated almost exclusively by metabolic transformation.
Apart from the active desglycinyl metabolite, ARL12495XX, which is formed by ubiquitous aminopeptidase enzymes, there are a number of oxidative biotransformation products. In addition, remacemide undergoes direct glucuronidation to form a carbamoyl glucuronide metabolite, a major pathway in man3. This interaction study used a placebocontrolled design in order to investigate the potential interaction between remacemide hydrochloride and VPA. Following multiple dosing, no significant effect was seen on VPA metabolism.
This study also offered the opportunity to provide a pharmacokinetic profile of remacemide and ARL12495XX in non-enzyme induced epileptic patients.
For both compounds, the multiple-dose profile was consistent with that predicted from the single dose, indicative of linear disposition and the absence of autoinduction of metabolism. Moreover, the mean terminal elimination half-life of both remacemide and ARL12495XX in the VPA-treated patients after single and chronic dosing were similar to those found previously in untreated volunteers3. This was in contradistinction to the lower half-lives previously reported in enzyme-induced carbamazepine-* and phenytoin-treated' patients. The most common adverse events with remacemide hydrochloride tend to be dizziness and gastrointestinal upse?. In this study, a higher number of adverse events were reported during the active treatment phase than with placebo. In particular, a number of patients were unable to tolerate the higher dose of remacemide hydrochloride due to CNS-related side-effects. These adverse events were not a result of a phmacokinetic interaction between the two drugs. It is possibly a consequence of the fast titration schedule used in this study.
